Background Although cancers are characterized by the deregulation of multiple signalling pathways, most current anticancer therapies involve the modulation of a single target. Because of the enormous biological diversity of cancer, strategic combination of agents targeted against the most critical of those alterations is needed. Due to their complex nature, plant products interact with numerous targets and influence several biochemical and molecular cascades. The interest in further development of botanical drugs has been increasing steadily and the FDA recently approved the first new botanical prescription drug. The present study is designed to explore the potential antileukemic properties of Hemidesmus indicus with a view to contributing to further development of botanical drugs. Hemidesmus was submitted to an extensive in vitro preclinical evaluation. Methodology/Principal Findings A variety of cellular assays and flow cytometry, as well as a phytochemical screening, were performed on different leukemic cell lines. We have demonstrated that Hemidesmus modulated many components of intracellular signaling pathways involved in cell viability and proliferation and altered the protein expression, eventually leading to tumor cell death, mediated by a loss of mitochondrial transmembrane potential and increased Bax/Bcl-2 ratio. ADP, adenine nucleotide translocator and mitochondrial permeability transition pore inhibitors did not reverse Hemidesmus-induced mitochondrial depolarization. Hemidesmus induced a significant [Ca2+]i raise through the mobilization of intracellular Ca2+ stores. Moreover, Hemidesmus significantly enhanced the antitumor activity of three commonly used chemotherapeutic drugs (methotrexate, 6-thioguanine, cytarabine). A clinically relevant observation is that its cytotoxic activity was also recorded in primary cells from acute myeloid leukemic patients. Conclusions/Significance These results indicate the molecular basis of the antileukemic effects of Hemidesmus and identify the mitochondrial pathways and [Ca2+]i as crucial actors in its anticancer activity. On these bases, we conclude that Hemidesmus can represent a valuable tool in the anticancer pharmacology, and should be considered for further investigations.
References
[1]
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70.
[2]
Aggarwal BB, Danda D, Gupta S, Gehlot P (2009) Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol 78: 1083–1094.
[3]
Zimmermann GR, Lehar J, Keith CT (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12: 34–42.
[4]
Keith CT, Borisy AA, Stockwell BR (2005) Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4: 71–78.
[5]
Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB (2008) Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett 267: 133–164.
[6]
Chen ST, Dou J, Temple R, Agarwal R, Wu KM, et al. (2008) New therapies from old medicines. Nat Biotechnol 26: 1077–1083.
[7]
US Department of Health and Human Services FaDACfDEaR (2004) Guidance for Industry. Botanical Drug Products.
[8]
Ichikawa H, Nakamura Y, Kashiwada Y, Aggarwal BB (2007) Anticancer drugs designed by mother nature: ancient drugs but modern targets. Curr Pharm Des 13: 3400–3416.
[9]
Kotnis MS, Patel P, Menon SN, Sane RT (2004) Renoprotective effect of Hemidesmus indicus, a herbal drug used in gentamicin-induced renal toxicity. Nephrology (Carlton) 9: 142–152.
[10]
Lampronti I, Khan MT, Bianchi N, Ather A, Borgatti M, et al. (2005) Bangladeshi medicinal plant extracts inhibiting molecular interactions between nuclear factors and target DNA sequences mimicking NF-kappaB binding sites. Med Chem 1: 327–333.
[11]
Prabakan M, Anandan R, Devaki T (2000) Protective effect of Hemidesmus indicus against rifampicin and isoniazid-induced hepatotoxicity in rats. Fitoterapia 71: 55–59.
[12]
Previati M, Corbacella E, Astolfi L, Catozzi M, Khan MT, et al. (2007) Ethanolic extract from Hemidesmus indicus (Linn) displays otoprotectant activities on organotypic cultures without interfering on gentamicin uptake. J Chem Neuroanat 34: 128–133.
[13]
Qureshi S, Rai MK, Agrawal SC (1997) In vitro evaluation of inhibitory nature of extracts of 18-plant species of Chhindwara against 3-keratinophilic fungi. Hindustan Antibiot Bull 39: 56–60.
[14]
Austin A (2008) A review on Indian sarsaparilla, Hemidesmus indicus (L.) R. Br. J Biol Sci 8: 1–12.
[15]
Das S, Devaraj SN (2006) Glycosides derived from Hemidesmus indicus R. Br. root inhibit adherence of Salmonella typhimurium to host cells: receptor mimicry. Phytother Res 20: 784–793.
[16]
Deepak D, Srivastava S, Khare A (1997) Pregnane glycosides from Hemidesmus indicus. Phytochemistry 44: 145–151.
[17]
Roy SK, Ali M, Sharma MP, Ramachandram R (2001) New pentacyclic triterpenes from the roots of Hemidesmus indicus. Pharmazie 56: 244–246.
[18]
Sircar D, Dey G, Mitra A (2007) A validated HPLC method for simultaneous determination of 2-hydroxy-4-methoxybenzaldehyde and 2-hydroxy-4-methoxybenzoic acid in root organs of Hemidesmus indicus. Chromatographia 65: 349–353.
[19]
Government of India, Ministry of Health & Family Welfare, Department of Health (1989) The Ayurvedic Pharmacopoeia of India. 107 p.
[20]
Macho A, Calzado MA, Munoz-Blanco J, Gomez-Diaz C, Gajate C, et al. (1999) Selective induction of apoptosis by capsaicin in transformed cells: the role of reactive oxygen species and calcium. Cell Death Differ 6: 155–165.
[21]
Zhao L, Wientjes MG, Au JL (2004) Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10: 7994–8004.
[22]
Macho A, Blanco-Molina M, Spagliardi P, Appendino G, Bremner P, et al. (2004) Calcium ionophoretic and apoptotic effects of ferutinin in the human Jurkat T-cell line. Biochem Pharmacol 68: 875–883.
[23]
Cuello M, Ettenberg SA, Nau MM, Lipkowitz S (2001) Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 81: 380–390.
[24]
Shapiro GI, Harper JW (1999) Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104: 1645–1653.
[25]
Toogood PL (2002) Progress toward the development of agents to modulate the cell cycle. Curr Opin Chem Biol 6: 472–478.
[26]
Borel F, Lacroix FB, Margolis RL (2002) Prolonged arrest of mammalian cells at the G1/S boundary results in permanent S phase stasis. J Cell Sci 115: 2829–2838.
[27]
Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, et al. (2000) RB-dependent S-phase response to DNA damage. Mol Cell Biol 20: 7751–7763.
[28]
Pedeux R, Al-Irani N, Marteau C, Pellicier F, Branche R, et al. (1998) Thymidine dinucleotides induce S phase cell cycle arrest in addition to increased melanogenesis in human melanocytes. J Invest Dermatol 111: 472–477.
[29]
Ogryzko VV, Wong P, Howard BH (1997) WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 17: 4877–4882.
[30]
Tsang WY, Wang L, Chen Z, Sanchez I, Dynlacht BD (2007) SCAPER, a novel cyclin A-interacting protein that regulates cell cycle progression. J Cell Biol 178: 621–633.
[31]
Geley S, Kramer E, Gieffers C, Gannon J, Peters JM, et al. (2001) Anaphase-promoting complex/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. J Cell Biol 153: 137–148.
[32]
Koff A, Giordano A, Desai D, Yamashita K, Harper JW, et al. (1992) Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257: 1689–1694.
[33]
Gartel AL, Radhakrishnan SK (2005) Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65: 3980–3985.
[34]
Radhakrishnan SK, Feliciano CS, Najmabadi F, Haegebarth A, Kandel ES, et al. (2004) Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle. Oncogene 23: 4173–4176.
[35]
Khan N, Afaq F, Mukhtar H (2007) Apoptosis by dietary factors: the suicide solution for delaying cancer growth. Carcinogenesis 28: 233–239.
[36]
Moncada S (2010) Mitochondria as pharmacological targets. Br J Pharmacol 160: 217–219.
[37]
Koh DW, Dawson TM, Dawson VL (2005) Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacol Res 52: 5–14.
[38]
Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A (1997) JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 411: 77–82.
[39]
Armstrong JS (2006) The role of the mitochondrial permeability transition in cell death. Mitochondrion 6: 225–234.
[40]
Qanungo S, Das M, Haldar S, Basu A (2005) Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis 26: 958–967.
[41]
Crompton M (1999) The mitochondrial permeability transition pore and its role in cell death. Biochem J 341(Pt 2): 233–249.
[42]
Nicotera P, Orrenius S (1998) The role of calcium in apoptosis. Cell Calcium 23: 173–180.
[43]
Choi JH, Lee HW, Park HJ, Kim SH, Lee KT (2008) Kalopanaxsaponin A induces apoptosis in human leukemia U937 cells through extracellular Ca2+ influx and caspase-8 dependent pathways. Food Chem Toxicol 46: 3486–3492.
[44]
Harper JL, Camerini-Otero CS, Li AH, Kim SA, Jacobson KA, et al. (2003) Dihydropyridines as inhibitors of capacitative calcium entry in leukemic HL-60 cells. Biochem Pharmacol 65: 329–338.
[45]
Jiang N, Zhang ZM, Liu L, Zhang C, Zhang YL, et al. (2006) Effects of Ca2+ channel blockers on store-operated Ca2+ channel currents of Kupffer cells after hepatic ischemia/reperfusion injury in rats. World J Gastroenterol 12: 4694–4698.
[46]
Hsin YH, Cheng CH, Tzen JT, Wu MJ, Shu KH, et al. (2006) Effect of aristolochic acid on intracellular calcium concentration and its links with apoptosis in renal tubular cells. Apoptosis 11: 2167–2177.
[47]
Thastrup O, Cullen PJ, Drobak BK, Hanley MR, Dawson AP (1990) Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Proc Natl Acad Sci U S A 87: 2466–2470.
[48]
Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322–1326.
[49]
Levi F, Focan C, Karaboue A, de La Valette V, Focan-Henrard D, et al. (2007) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 59: 1015–1035.
[50]
Cree IA (2009) Chemosensitivity and chemoresistance testing in ovarian cancer. Curr Opin Obstet Gynecol 21: 39–43.
[51]
Nagourney RA (2006) Ex vivo programmed cell death and the prediction of response to chemotherapy. Curr Treat Options Oncol 7: 103–110.
[52]
Nygren P, Larsson R (2008) Predictive tests for individualization of pharmacological cancer treatment. Expert Opinion on Medical Diagnostics 2: 1–12.
[53]
Bosanquet AG, Bell PB (2004) Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells. J Exp Ther Oncol 4: 145–154.
[54]
Bosanquet AG, Nygren P, Weisenthal LM (2008) Individualized tumor response testing in leukemia and lymphoma. In: Kaspers GJ, Coiffier B, Heinrich MC, Estey EH, editors. Innovative leukemia and lymphoma therapy. New York: Informa Healthcare. pp. 23–44.
[55]
Bosanquet AG (1994) Short-term in vitro drug sensitivity tests for cancer chemotherapy. A summary of correlations of test result with both patient response and survival. Forum Trends in Experimental and Clinical Medicine 4: 179–198.
[56]
Meshinchi S, Appelbaum FR (2009) Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 15: 4263–4269.
[57]
Zhou JR, Yu L, Zhong Y, Blackburn GL (2003) Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J Nutr 133: 516–521.
[58]
Williams SN, Shih H, Guenette DK, Brackney W, Denison MS, et al. (2000) Comparative studies on the effects of green tea extracts and individual tea catechins on human CYP1A gene expression. Chem Biol Interact 128: 211–229.
[59]
de Kok TM, van Breda SG, Manson MM (2008) Mechanisms of combined action of different chemopreventive dietary compounds. Eur J Nutr 47: Suppl 251–59.
